Genocure Establishes Strategic Partnership

with Cosmetics Specialist ‘BNK’ for High-Purity PDRN 

- Expected to secure a bridgehead in the raw materials and cosmetics market

related to PDRN, a cosmetic raw material in a spotlight -

Sept. 29, 2024

(L) CEO of BNK, Kim Young-hun (R) CEO of Genocure, Oh Bo-gyeong

A regenerative biomaterial specialized company, Genocure Co., Ltd. (CEO Oh Bo-gyeong, www.genocure.co.kr) established a strategic partnership with a high-quality skincare cosmetics specialized company, BNK Co., Ltd.(CEO Kim Young-hun) for distribution of high-purity PDRN as raw materials and cosmetics on September 29th. 

Genocure is a bio venture startup, that is now entering the global regenerative medical market through supply of PDRN as a raw material for pharmaceuticals, medical devices, and cosmetics, and the development of PDRN-related finished products, based on the technology of extracting and producing PDRN of high purity and the research and development on the next-generation PDRN.

BNK is known to have established a strategic partnership with Genocure, highly evaluating the possibility of combining cosmetics with high-quality PDRN based on Barulab’s(www.barulab.com) skincare cosmetics distribution.

Regarding this, Oh Bo-gyeong, CEO of Genocure, stated, “Genocure is planning to supply domestically produced high-purity PDRN starting 2025 and expects to achieve visible results with global companies in research and development for next-generation PDRN production soon enough.” She also added that Genocure will work hard to increase corporate value by actively promoting ‘various regenerative medical businesses using PDRN’ by supplying pharmaceutical grade PDRN through the bGMP certification.